Nicole Marquardt
About me
Dr. rer. nat., Senior Research Specialist
I completed my PhD in 2011 in Hannover, Germany, and got recruited to the group of Jakob Michaëlsson at the Center for Infectious Medicine (CIM, MedH) the same year. In 2018, I finished my Assistant Professor at CIM and became Team Leader and Senior Research Specialist at MedH in 2019. Early 2023, my Team and I joined the group of Petter Höglund at the Center for Hematology and Regenerative Medicine (HERM).
I have a long-standing expertise in the field of NK cell research both in blood and tissues, and my research focuses primarily on human NK cells in tissues in homeostasis and disease.
Human NK cells are well-characterized in the peripheral blood, however, rather little is known about NK cells in tissues. While peripheral blood NK cells likely play an important role in hematologic malignancies, tissue-resident NK cells presumably represent a front line of defense in tissues such as the lung e.g. during respiratory viral infections or play a pivotal role in the defense against solid tumors. Hence, the identification of distinct NK cell subsets homing to and residing in human tissues allows us to gain new perspectives about disease development, progression, and potential therapeutic approaches in tissue-specific pathologies.
In our team, we focus primarily on NK cells in human lung (healthy, tumor-free, tumor, respiratory viral infections), but also other tissues as well as tissue-homing capacities of blood NK cells. In detail, we are interested in NK cell function and regulation in different areas of the respiratory tract and in solid tumors. Furthermore, we aim at understanding the responsiveness of tissue-resident NK cells in e.g. viral infections with influenza A virus or SARS-CoV-2. Our vision is that our generated knowledge will be translated into development and optimization of prevention and treatment strategies for patients affected by lung cancer or respiratory viral infections.
Research
Prevention of NK cell-induced lung tissue-damage upon severe respiratory viral infections
Severe respiratory diseases such as COVID-19 and flu are commonly associated with lung tissue-damage, partly caused by an excessive immune response. While Natural Killer (NK) cells are believed to play a crucial role in host responses towards viral infections, surprisingly little is known about human NK cell regulation in respiratory viral infections. The overall aim with this project is to identify regulatory mechanisms of human blood and lung NK cells that can be targeted for treatment of patients suffering from severe acute respiratory viral infections, ultimately balancing immune pathology and immune protection in severe respiratory viral infections.
Ongoing collaborations will provide us access to non-infected human lung tissue, lung tissue from COVID-19-infected patients as well as to peripheral blood from influenza- or SARS-CoV-2-infected patients. The combination of unique human clinical material, the ability to conduct in vitro infections with highly relevant viruses, and usage of cutting-edge technologies will be the central elements of this project. Our vision is to define the biology of human NK cell subsets in and trafficking to the lung upon viral infection, ultimately aiming at reducing disease severity, hospitalization, and mortality.
- Tissue-resident NK cells in the human lung and lung tumors
Lung cancer is the leading type of cancer worldwide in terms of incidence and mortality. Natural Killer (NK) cells are well known for their capacity to target and lyse tumor cells, and they are currently representing a promising tool for treatment of hematopoietic cancers. However, treatment of solid tumors including lung tumors is still in its infancy. Major limitations are inefficient trafficking of NK cells to the tumor site as well as lack of NK cell infiltration into the tumor, antigen escape mechanisms, and an immunosuppressive tumor microenvironment. While we have identified distinct NK cell subsets in the human lung in previous studies, little is known about the regulation of NK cells in the human lung and in lung tumors. This project aims at mapping the landscape of NK cells in different areas of healthy human lung and in human lung tumors. Based on the results, we aim at harnessing and expanding the NK cell subsets most suitable for infiltrating and killing lung tumor cells for future treatment of lung cancer.
In collaboration with physicians and scientists at Karolinska University Hospitals Huddinge/Solna we collect healthy lung tissue from human organ donors as well as tumor-free tissue and lung tumors from patients undergoing surgery for suspected lung cancer. We will particularly focus on NK cell lung-homing, tumor-infiltration, tissue-residency, and cytotoxicity. Cutting-edge technologies such as high parameter flow/spectral cytometry, RNA-sequencing, and live cell-imaging are key in this project proposal.
The combination of unique human clinical material and application of cutting-edge technologies will be the central elements of this project. Our vision is to harness suitable human NK cell subsets in lung cancer, ultimately aiming at reducing disease severity, hospitalization, and mortality.
Teaching
Course director for doctoral course "Tissue-specific immunology" (3072, Aii, 1.5 HEC, organized every second year)
Feedback from course (2023):
"The presenters that had a story to tell backing it up with real life data, not only reviews."
"I appreciated that the course leaders were flexible and tried their best to make everyone happy and content"
"I liked the setup of the course, good speakers and interesting topics! Good amount of breaks and overall a nice flow throughout the course."Current and past members of the team
Current members
Nicole Wild, MSc
Doctoral student
Since 04/2022
Elena Bonaiti, PhD
Postdoc
Since 01/2024
Past members
Julia Schaden, BSc
Master student
2023-2024
Fabian Zoppelt, BSc
Internship student
02-07/2024
Camille Guedé, BSc
Internship student
Oct 2023-June 2024
Demi Brownlie, PhD
Postdoc
Nov 2019-October 2023
Now Postdoc at the Beatson West of Scotland Cancer Centre, UK
Pablo Clavero
Internship student
Feb-June 2022
Giampiero Valenzano
Internship student
January-July 2021
Kathleen Schlüter, BSc
Internship student
04-06/2021
Andreas von Kries, BSc
Internship/Master student
01/2020 - 02/2021
Now PhD student in the group of Adelheid Cerwenka, Mannheim, Germany.
Marlena Scharenberg, BSc
Master student
01-10/2017
Articles
- Journal article: GENES AND IMMUNITY. 2024;:1-5
- Article: SCIENCE IMMUNOLOGY. 2024;9(99):eadn2362
- Article: JOURNAL OF INFECTIOUS DISEASES. 2024;230(2):e318-e326
- Article: NATURE IMMUNOLOGY. 2024;25(8):1445-1459
- Article: ONCOIMMUNOLOGY. 2023;12(1):2233402
- Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;96(1):e13195
- Article: CELL REPORTS MEDICINE. 2022;3(2):100508
- Article: FRONTIERS IN IMMUNOLOGY. 2022;13:834862
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2021;118(11):e2016580118
- Article: IMMUNITY. 2021;54(2):259-275.e7
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2021;118(6):e2018587118
- Article: FRONTIERS IN IMMUNOLOGY. 2021;12:752104
- Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1306
- Article: CELL. 2020;183(1):158-168.e14
- Article: SCIENCE IMMUNOLOGY. 2020;5(51):eabe1670
- Article: SCIENCE IMMUNOLOGY. 2020;5(50):eabd6832
- Article: NATURE COMMUNICATIONS. 2019;10(1):3897
- Article: NATURE COMMUNICATIONS. 2019;10(1):3841
- Article: JOURNAL OF HEPATOLOGY. 2019;71(2):301-312
- Article: FRONTIERS IN IMMUNOLOGY. 2019;10:1116
- Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2017;139(4):1321-1330.e4
- Article: MUCOSAL IMMUNOLOGY. 2017;10(2):322-331
- Article: IMMUNITY. 2017;46(2):287-300
- Article: JOURNAL OF IMMUNOLOGY. 2016;197(8):3069-3075
- Article: JOURNAL OF IMMUNOLOGY. 2015;195(7):3262-3272
- Article: JOURNAL OF IMMUNOLOGY. 2015;194(6):2467-2471
- Article: CELL COMMUNICATION AND SIGNALING. 2014;12:63
- Article: FRONTIERS IN IMMUNOLOGY. 2014;5:662
- Article: JOURNAL OF CLINICAL INVESTIGATION. 2013;123(9):3889-3901
- Article: BRAIN, BEHAVIOR, AND IMMUNITY. 2011;25(6):1233-1241
- Article: TISSUE ENGINEERING - PART C: METHODS. 2011;17(4):485-493
- Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2010;40(5):1428-1439
- Article: JOURNAL OF STEM CELLS AND REGENERATIVE MEDICINE. 2010;6(2):101-102
- Article: ARTHRITIS & RHEUMATOLOGY. 2009;60(12):3563-3571
- Show more
All other publications
- Preprint: BIORXIV. 2024
- Preprint: BIORXIV. 2024
- Conference publication: EXPERIMENTAL DERMATOLOGY. 2024;33(3)
- Meeting abstract: BLOOD. 2021;138:4796
- Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2021;51:170
- Preprint: MEDRXIV. 2020
- Preprint: BIORXIV. 2019
- Letter: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2017;140(1):318
- Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2016;46:67-68
- Other: ALLERGY. EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2015;70(11):1353-1355
- Conference publication: JOURNAL OF IMMUNOLOGY. 2013;190:173.17
- Conference publication: JOURNAL OF IMMUNOLOGY. 2013;190:52.46
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:180
- Conference publication: IMMUNOLOGY. 2012;137:92
- Conference publication: TISSUE ENGINEERING - PART A.. 2011;17(3-4):575
- Letter: ARTHRITIS & RHEUMATOLOGY. 2010;62(8):2563-2565
- Conference publication: WIENER KLINISCHE WOCHENSCHRIFT. 2008;120:107
Grants
- Induction of cytotoxic NK cells with a tissue-resident phenotype for treatment against human lung tumorsMagnus Bergvalls Stiftelse1 January 2024 - 31 December 2024
- Harnessing human adaptive-like tissue-resident Natural Killer cells for treatment of lung cancerThe Swedish Cancer Society1 January 2023 - 31 December 2025
- Swedish Cancer Society1 January 2023
- Modifiera lunginfiltration av NK-celler i luftvägsinfektioner för att förhindra lungvävnadsskadaKI Research Foundation1 January 2022 - 31 December 2023
- Mapping NK cell heterogeneity and functions in human lung tissues in health and diseaseKID1 January 2022 - 31 December 2025
- Swedish Research Council1 January 2022 - 31 December 2024
- Swedish Research Council1 December 2021 - 30 November 2024
- Prevention of NK cell-induced lung tissue-damage upon severe respiratory viral infections (SARS-CoV-2, Influenza A virus)Centrum för innovativ medicin (CIMED)1 January 2021 - 31 December 2023
- Stiftelsen Tornspiran1 January 2021 - 31 December 2021
- Harnessing intratumoral tissue-resident NK cells for treatment of lung cancer with inhibitory checkpoint blockadeCentrum för innovativ medicin1 January 2021 - 31 December 2023
- Metabolic regulation of tumor-infiltrating NK cells in human sarcomaMagnus Bergvalls Stiftelse1 January 2020 - 31 December 2020
- Human lung NK cells in severe respiratory viral infectionsStiftelsen Clas Groschinskys Minnesfond1 January 2020 - 31 December 2021
- Humana NK cellers funktion och reglering vid infekction med influensavirusKI Research Foundation1 January 2019 - 31 December 2020
- Funktion och manipulering av naturliga killer celler i virusinfektion i human lungaStiftelsen Tornspiran1 January 2019 - 31 December 2019
- Role and manipulation of human lung NK cells in influenza infectionÅke Wibergs Stiftelse1 January 2019 - 31 December 2019
- Deutsche Forschungsgemeinschaft1 January 2011 - 31 December 2013
Employments
- Senior Research Specialist, Department of Medicine, Huddinge, Karolinska Institutet, 2022-
Degrees and Education
- PhD, Immunology, Characterization of immunoregulatory NK cells, non-Treg T cells and mesenchymal stem cells, Department of Clinical Immunology and Rheumatology, Hannover Medical School, 2011